AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03945123 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Red ginseng
Description: Red ginseng tablet 120g
Study NCT01286714 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CLIP OST
Study NCT04502472 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Convalescent plasma transfusion
Description: Transfusion of COVID-19 convalescent plasma to participants currently hospitalized with COVID-19 infection with severe or life-threatening clinical syndrome.
Study NCT04313816 — intervention group
Intervention type: OTHER
Intervention: questionnaire
Description: no intervention at all apart from filling a brief questionnaire
Study NCT03807752 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: MPH_active
Description: One daily intake at breakfast of supplementary marine protein hydrolysate (MPH), a dosage of X mg, duration 8 weeks. The form is powder, flavored with lemon, and to be mixed with 100 ml water. Random sequence of arms.
Study NCT03807752 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: MPH_placebo
Description: One daily intake at breakfast of supplementary placebo, a dosage of X mg, duration 8 weeks. The form is powder, flavored with lemon, and to be mixed with 100 ml water.
Study NCT04044651 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenvatinib
Description: lenvatinib 12 mg (or 8 mg) by mouth (Po) once daily
Study NCT04044651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: lenvatinib 12 mg (or 8 mg) by mouth (Po) once daily
Study NCT04044651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: nivolumab 480 mg IV infusions for 30 minutes q4w
Study NCT03498196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: avelumab 10 mg/kg intravenously every 2 weeks for 3 cycles or 42 days.
Study NCT03939312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atogepant
Description: Atogepant Tablets
Study NCT06245681 — intervention group
Intervention type: DRUG
Intervention: gender affirming hormone therapy
Description: both groups are receiving gender-affirming hormone therapy; we do not compare the groups, but look at whether hormone therapy with testosterone or estrogen might have an effect on myocardial function, organ lipid content and subcutaneous to visceral fat ratio
Study NCT02030249 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low calorie diet administered from 0 to 2 months
Description: The 2-month low calorie diet is administered from the 0 months to the 2 months time point. It is designed to elicit a weight loss of 8% of initial body weight. Please see parent study for further intervention details: http://clinicaltrials.gov/ct2/show/NCT01777893?term=preview\&rank=1
Study NCT02030249 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low calorie diet administered from 0 to 2 months
Description: The 2-month low calorie diet is administered from the 0 months to the 2 months time point. It is designed to elicit a weight loss of 8% of initial body weight. Please see parent study for further intervention details: http://clinicaltrials.gov/ct2/show/NCT01777893?term=preview\&rank=1
Study NCT03976505 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: filling a virtual pillbox displayed on the screen as prescribed in the prescription
Description: filling a virtual pillbox displayed on the screen as prescribed in the prescription
Study NCT02030249 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Protein / Low Glycaemic Index
Description: Please see description of the Arm by the same name.
Study NCT02030249 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate Protein / High Glycaemic Index
Description: Please see description of the Arm by the same name.
Study NCT01773798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/insulin aspart 15
Description: Each subject subject will be randomly allocated to five single doses. Administered subcutaneously (s.c, under the skin) on five dosing visits separated by 15-25 days. The dose level will be 0.5 U/kg Body Weight (BW).
Study NCT01773798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/insulin aspart
Description: Each subject subject will be randomly allocated to five single doses. Administered subcutaneously (s.c, under the skin) on five dosing visits separated by 15-25 days. The dose level will be 0.5 U/kg Body Weight (BW).
Study NCT01773798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Each subject subject will be randomly allocated to five single doses. Administered subcutaneously (s.c, under the skin) on five dosing visits separated by 15-25 days. The dose level will be 0.425 U/kg Body Weight (BW).
Study NCT01773798 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: Each subject subject will be randomly allocated to five single doses. Administered subcutaneously (s.c, under the skin) on five dosing visits separated by 15-25 days. The dose level will be 0.075 U/kg Body Weight (BW).
Study NCT01773798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: Each subject subject will be randomly allocated to five single doses. Administered subcutaneously (s.c, under the skin) on five dosing visits separated by 15-25 days. The dose level will be 0.075 U/kg Body Weight (BW).
Study NCT01773798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Each subject subject will be randomly allocated to five single doses. Administered subcutaneously (s.c, under the skin) on five dosing visits separated by 15-25 days.
Study NCT03736811 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Polyglactin 910 or polydioxanone
Description: Vicryl or PDS II
Study NCT03736811 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polyester or polypropylene
Description: Ethibond Excel or prolene
Study NCT02249208 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tc+blue dye
Description: Sentinel Lymph Node (SLN) identification and resection using the standard technique of sub-areolar injection of technetium-99m (Tc-99m) and sub-areolar injection of vital blue dye before surgery
Study NCT02249208 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tc+SPIO
Description: Sentinel Lymph Node (SLN) identification and resection using isotope technique of sub-areolar injection of technetium-99m (Tc-99m) and the magnetic technique with the sub-areolar injection of SPIO (Sienna+®), before surgery
Study NCT02249208 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SPIO alone
Description: Sentinel Lymph Node (SLN) identification and resection using the magnetic technique with the sub-areolar injection of SPIO (Sienna+®) before surgery
Study NCT05621590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLC 901
Description: MLC901, also known as NeuroAiDII, is a capsule form of drug which should be taken orally and combines nine herbal components
Study NCT05621590 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo capsules filled with stevia sweetened powder
Study NCT04165005 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: decentering
Description: examined a mindfulness-based intervention focused on a decentering component, that is suitable for elders, aimed to influence on cognitive measures and psychological distress.
Study NCT04165005 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: guided imagery
Description: relaxing guided imagery including breathing exercises.
Study NCT01797315 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus
Study NCT02181036 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: family work shop
Description: 2-3 hours per session, one session per week, a total of 6 weeks of family work shop
Study NCT02119650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: 5 mg tablets to be administered by mouth at dose selected from safety run-in phase (Ruxolitinib 15 mg twice daily (BID))
Study NCT02119650 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 5 mg matching placebo tablets to be administered by mouth
Study NCT02119650 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: 500 mg/m\^2 administered as an intravenous infusion over 10 minutes
Study NCT02119650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 mg/m\^2 administered as an intravenous infusion over 10 minutes
Study NCT02119650 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 75 mg/m\^2 infused over 2 hours beginning 30 ± 5 minutes after the end of the pemetrexed infusion
Study NCT02119650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75 mg/m\^2 infused over 2 hours beginning 30 ± 5 minutes after the end of the pemetrexed infusion
Study NCT01932203 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin
Description: 100mg once a day
Study NCT01932203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cilostazol
Description: 200mg once a day
Study NCT04497766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebulized Magnesium sulfate
Description: MgSO4 100mg in 20 ml normal saline will be given via ultrasonic nebulizer over 10 minutes,and PAS score will be assessed at 30,60,120,240,360 minutes
Study NCT04497766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulphate
Description: pts age 2 to 12 years will receive intravenous magnesium sulphate 50 mg/kg over half hour
Study NCT00585156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Twelve hours prior to their first total knee surgery, patients will need to take an oral dose of Celebrex, 1 pill of 200mg. Following the patient's first total knee surgery, they will continue taking oral doses of Celebrex, 1 pill of 200 mg every twenty-four hours (200mg/day) for a two-week period.
Study NCT02332512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Study NCT03949998 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dry Needling
Description: Comparison between dry needling and/or manual therapy of the cervical region.
Study NCT03949998 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dry Needling
Description: Comparison between dry needling and/or manual therapy of the cervical region.
Study NCT03949998 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Therapy
Description: soft tissue release, cervical traction and/or cervical mobilization
Study NCT04042038 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavior therapy (psychological treatment)
Description: Participants will receive up to 20 hours of manualized and structured CBT based on exposure and response prevention by experienced clinicians
Study NCT00179517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole 1mg
Study NCT00039026 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Lead In (0.02 mL) for 4 weeks / Placebo (0.02 mL) for 4 weeks / Placebo (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily
Study NCT00039026 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Lead In (0.02 mL) for 4 weeks / Placebo mcg (0.02 mL) for 4 weeks / Placebo (0.04 mL) for 26 weeks - All are subcutaneously injected twice daily
Study NCT03976505 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eye-tracker
Description: In the touch-screen condition an eye-tracker is used to record eye fixations and scanpaths in real time.
Study NCT03976505 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: eye-tracker
Description: In the touch-screen condition an eye-tracker is used to record eye fixations and scanpaths in real time.
Study NCT03976505 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cognitive tests and questionary
Description: Once the 2nd pillbox filling is finished a battery of cognitive tests and questionnaires is administered to participants to identify Pd subtypes of impaired performances.
Study NCT03976505 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cognitive tests and questionary
Description: Once the 2nd pillbox filling is finished a battery of cognitive tests and questionnaires is administered to participants to identify Pd subtypes of impaired performances.
Study NCT00283101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGN-40 (anti-huCD40 mAb)
Description: 1-8 mg/kg IV; Days 1, 4, 8, 15, 22, 29 of Cycle 1 and Days 1, 15, 29 and 43 of Cycles 2-6.
Study NCT00179517 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Study NCT02685787 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychosocial Intervention
Description: The caregiver in the intervention arm will meet the counselors six times. The first and the last sessions will be attended by the caregiver only whereas the remaining four sessions will be attended by the caregiver and other family members. Interventions will be tailored for the caregivers based upon: 1) depression and anxiety; 2) burden; 3) self care and health-related behavior; 4) social support; and 5) behavioral symptoms. The design and management of the structured intervention will follow a published counseling caregiver manual, based on the experiences matured at New York University. Every session will be documented.
Study NCT02685787 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational Intervention on AD
Description: The caregiver enrolled in this arm:1) will not receive counseling or support; 2) will participate to group sessions; 3) the six hours sessions will divulge information on AD using a slide-show. Each session will focus on the following topic: (a) diagnosis and treatment b) cognitive deficit management, c) behavioral disturbance management, d) daily living management, e) non-pharmacological treatment, f) legal issues and available health and social services.~Additionally, contrary to other arm, caregivers will not receive any telephone calls after the end of the educational sessions.
Study NCT03368599 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchoscope guided advancement
Description: During the anesthetic induction for thoracic surgery, Lt. DLT is intubated using the bronchoscope-guided method. The method is as follows.~1. Lt. DLT is intubated through vocal cord using the direct laryngoscopy.~2. Pass the fiberoptic bronschoscope through a bronchial lumen of Lt. DLT.~3. Secure the pathway into the Lt. main bronchus by advancing the bronchoscope into the Lt. main bronchus.~4. Lt. DLT can be advanced through the guide of the bronchoscope into Lt. main bronchus.~5. After the advancement, the position of Lt. DLT can be confirmed using the fiberoptic bronchoscope. If necessary, the depth and direction of Lt. DLT should be modified.
Study NCT03368599 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional advancement
Description: During the anesthetic induction for thoracic surgery, Lt. DLT is intubated using the conventional method. The method is as follows.~1. Lt. DLT is intubated through vocal cord using the direct laryngoscopy.~2. Rotate Lt. DLT 90 degrees to the left side.~3. Advance Lt. DLT blindly to main bronchus level.~4. After the advancement, the position of Lt. DLT can be confirmed using the fiberoptic bronchoscope. If necessary, the depth and direction of Lt. DLT should be modified.
Study NCT02917629 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02917629 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02917629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformide Hydrochloride/Pioglitazone Hydrochloride Extended-Release Tablet
Description: Given PO
Study NCT02917629 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02917629 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02276014 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Beta-carotene
Study NCT03272464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib may work by binding to your cancer cells to inhibit the cancer cells' signals to decrease cell growth.
Study NCT03272464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Dabrafenib may work by stopping your cancer cells from duplicating.
Study NCT02332512 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03272464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB039110
Description: Itacitinib may work by stopping your tumor cells from living and growing.
Study NCT04361149 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capsaicin Topical Cream (0.075%)
Description: Capsaicin cream will be administered as a topical skin cream
Study NCT04361149 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Delsys Trigno Galileo System
Description: A wireless surface EMG device. The sensors will be placed on the trapezius and the infraspinatus muscle, and a recording will be performed.
Study NCT04361149 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Delsys Trigno Galileo System
Description: A wireless surface EMG device. The sensors will be placed on the trapezius and the infraspinatus muscle, and a recording will be performed.
Study NCT04361149 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Excaliber, Natus Medical
Description: Intramuscular EMG machine. The intramuscular electrode will be inserted into the trapezius and a recording will be performed.
Study NCT04361149 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Excaliber, Natus Medical
Description: Intramuscular EMG machine. The intramuscular electrode will be inserted into the trapezius and a recording will be performed.
Study NCT04361149 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Cream
Description: Placebo cream will be administered as a topical skin cream
Study NCT00615654 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: aquatic physical therapy
Description: The aquatic physiotherapy program for the SG was applied twice a week, in groups of six to seven people, with sessions lasting 40 minutes, over a 12-week period. The Control Group protocol included maintenance of the individuals' medication therapy and absence of any physical activity during the study period.
Study NCT01454908 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Oxford Partial Knee
Description: The Oxford partial knee contains tibial and medial components and a mobile meniscal bearing.
Study NCT03964064 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiotherapy
Description: GTV: Combining localization and fusion images to delineate the tumors seen PTV = GTV + 0-10mm Target volume radiation dose: The range of BED value of radiotherapy was 80-100 when the distance between the tumor and gastrointestinal tract was more than 5 mm (alpha/beta=10) and 60-80 when the distance between the tumor and gastrointestinal tract was less than 5 mm (alpha/beta=10).~Normal Tissue Limit: Reference to TG101 Report
Study NCT03964064 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3D-printing Template-assisted CT-guided I125 Seed Implantation
Description: CT-guided radioactive 125I particle therapy with 3D printing template for pancreatic cancer Preoperative planning Design and fabrication of 3D-PNCT Particle implantation Postoperative dose assessment: CT scan was performed after operation, and the image was transmitted to BTPS for dose verification . The dosimetric parameters included tumor volume, D90, mPD, V100, V150 and V200.
Study NCT04059458 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biphasic calcium phosphate (Straumann Bone Ceramic) + collagen membrane (Straumann Jason Membrane)
Description: Device: Biphasic calcium phosphate (Straumann Bone Ceramic) + collagen membrane (Straumann Jason Membrane) Following open flap debridement of mandibular grade II furcation defects, regenerative therapy is performed with biphasic calcium phosphate + collagen membrane.
Study NCT04059458 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biphasic calcium phosphate (Straumann Bone Ceramic) + collagen membrane (Straumann Jason Membrane)
Description: Device: Biphasic calcium phosphate (Straumann Bone Ceramic) + collagen membrane (Straumann Jason Membrane) Following open flap debridement of mandibular grade II furcation defects, regenerative therapy is performed with biphasic calcium phosphate + collagen membrane.
Study NCT04059458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biphasic calcium phosphate (Straumann Bone Ceramic) + enamel matrix proteins (Straumann Emdogain)
Description: Drug: Biphasic calcium phosphate (Straumann Bone Ceramic) + enamel matrix proteins (Straumann Emdogain) Following open flap debridement of mandibular grade II furcation defects, regenerative therapy is performed with biphasic calcium phosphate + enamel matrix proteins.